close read more

Servier CDMO expands preparative chromatography platform at Normandy site to support market need


Servier CDMO expands preparative chromatography platform at Normandy site to support market need

The benefit is the speeding up of clinical supply and subsequent manufacture of complex molecules for medicines at commercial scale

Servier CDMO, our contract development and manufacturing organization (CDMO) division of Servier, announces that the company has invested $7.5 million USD in intensified technology included continuous chromatography with simulated moving beds (SMB) and super critical fluid chromatography (SFC) with solvent recycling of up to 90% to lower environmental impact.

Industiral preparative chromatography platform at Bolbec, France


Servier CDMO expects at least a 50% increase in productivity with the existing configuration of the high-volume batch columns that are used to manufacture drug substances. The investment supports the chemical purification of 50kg (kilograms) per day, and the chiral separation of 10kg per day to support clinical trials and market supply upon drug approvals.

The highly qualified team at the Bolbec site, in Normandy, is composed of experts in chemical processes and is certified to handle highly potent compounds to occupational exposure band five (OEB 5). Bolbec is a fully United States Food & Drug Administration (FDA) current good manufacturing practice (cGMP) site for human pharmaceuticals.

Servier CDMO believes that this exceptional expertise and technology give pharmaceutical companies access to the means to accelerate the development and commercialization of novel therapies that will meet significant unmet patient needs for highly potent compounds.


About Servier CDMO

In 2014, Servier embarked on an initiative that would offer the company’s highly-developed operations, quality culture and global drug and supply chain development skill set, ranging from complete manufacturing operations to the supply of discrete research and processing tasks (from starting materials and clinical trial batches to finished products), as outsource services in a contract services division, Servier CDMO, with manufacturing and research network of 11 facilities around the world that supplies even the most challenged markets and patient populations.


Last news

Meeting the challenge of adherence: a Servier study presented at the ESH 2022 Annual Meeting!
Appointment of Angelo Paci, Oncology & Immuno-Oncology Program Leader
Patient associations’ perception of pharmaceutical companies: Servier is making progress!